215 related articles for article (PubMed ID: 38390025)
21. Hospital-based costs associated with venous thromboembolism prophylaxis regimens.
Merli G; Ferrufino CP; Lin J; Hussein M; Battleman D
J Thromb Thrombolysis; 2010 May; 29(4):449-58. PubMed ID: 19847624
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
[TBL] [Abstract][Full Text] [Related]
23. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence.
AlLehaibi LH; Alomar M; Almulhim A; Al-Makki S; Alrwaili NR; Al-Bassam S; Alsultan S; Al Saeed J; Alsheef M; Abraham I; Alamer A
Ann Pharmacother; 2023 Apr; 57(4):361-374. PubMed ID: 35942505
[TBL] [Abstract][Full Text] [Related]
25. Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study.
Al Sulaiman K; Aljuhani O; Korayem GB; Hafiz A; Alalawi M; Badreldin HA; Altebainawi AF; Vishwakarma R; Alissa A; Alghamdi A; Alenazi AA; Al Enazi H; Alanazi S; Alhammad A; Alghamdi J; AlFaifi M; Al Sehli FA; Aldossari MA; Alhubaishi AA; Al-Ali AY; Al-Dorzi HM
Thromb J; 2022 Dec; 20(1):74. PubMed ID: 36482388
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
[TBL] [Abstract][Full Text] [Related]
27. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.
Junqueira DR; Perini E; Penholati RR; Carvalho MG
Cochrane Database Syst Rev; 2012 Sep; (9):CD007557. PubMed ID: 22972111
[TBL] [Abstract][Full Text] [Related]
28. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.
Forster R; Stewart M
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD004179. PubMed ID: 27027384
[TBL] [Abstract][Full Text] [Related]
29. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism.
Burleigh E; Wang C; Foster D; Heller S; Dunn D; Safavi K; Griffin B; Smith J
Am J Health Syst Pharm; 2006 Oct; 63(20 Suppl 6):S23-9. PubMed ID: 17032931
[TBL] [Abstract][Full Text] [Related]
30. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
31. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.
Laporte S; Liotier J; Bertoletti L; Kleber FX; Pineo GF; Chapelle C; Moulin N; Mismetti P
J Thromb Haemost; 2011 Mar; 9(3):464-72. PubMed ID: 21232002
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
[TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
Mason SW; Barber A; Jones E; Chen SL; Moll S; Northam K
Am J Med; 2020 Jun; 133(6):e249-e259. PubMed ID: 31862336
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.
Wang TF; Milligan PE; Wong CA; Deal EN; Thoelke MS; Gage BF
Thromb Haemost; 2014 Jan; 111(1):88-93. PubMed ID: 24136071
[TBL] [Abstract][Full Text] [Related]
36. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
[TBL] [Abstract][Full Text] [Related]
37. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.
Junqueira DR; Zorzela LM; Perini E
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007557. PubMed ID: 28431186
[TBL] [Abstract][Full Text] [Related]
38. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin.
Thorevska N; Amoateng-Adjepong Y; Sabahi R; Schiopescu I; Salloum A; Muralidharan V; Manthous CA
Chest; 2004 Mar; 125(3):856-63. PubMed ID: 15006942
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients.
Montero Ruiz E; Baldominos Utrilla G; López Álvarez J; Santolaya Perrin R
Thromb Res; 2011 Nov; 128(5):440-5. PubMed ID: 21880352
[TBL] [Abstract][Full Text] [Related]
40. Heparin versus enoxaparin for prevention of venous thromboembolism after trauma: A randomized noninferiority trial.
Olson EJ; Bandle J; Calvo RY; Shackford SR; Dunne CE; Van Gent JM; Zander AL; Sikand H; Bongiovanni MS; Sise MJ; Sise CB
J Trauma Acute Care Surg; 2015 Dec; 79(6):961-8; discussion 968-9. PubMed ID: 26317819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
